

Cambodia Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Cambodia				
2. Grant number: 1718-KHM-04a-X / /				
3. Date of Decision Letter: December 8, 2016				
4. Date of the Partnership Framework Agreement: November 6, 2013				
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine				
6. Vaccine type: Pentavalent				
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID				
8. Programme duration¹: 2010 -2018				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2010-2016	2017	2018	Total ²
Programme Budget (US\$)	18,230,601 ³	1,533,000	1,827,500	21,591,101
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2010-2016	2017		
Number of Pentavalent vaccines doses		831,300		
Annual Amounts (US\$)	18,230,601 ⁵	1,533,000		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.


³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1718-KHM-04a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition phase self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>								
Type of supplies to be purchased with Country funds in each year	2017	2018						
Number of vaccine doses	98,000	116,800						
Value of vaccine doses (US\$)	173,934							
Total co-financing payments (US\$) (including freight)	186,000	222,000						
<p>15. Operational support for campaigns: Not applicable</p>								
<p>16. Additional reporting requirements: Not applicable</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>			Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates							
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May							
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat							
<p>17. Financial clarifications: Country shall provide the following clarifications to Gavi*: The country is requested to address the financial clarifications listed in the management letter within the requested timeframe. <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>								
<p>18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.</p>								

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

December 8, 2016

Cambodia Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Cambodia				
2. Grant number: 1718-KHM-12c-X / /				
3. Date of Decision Letter: December 8, 2016				
4. Date of the Partnership Framework Agreement: November 6, 2013				
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine				
6. Vaccine type: Pneumococcal				
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID				
8. Programme duration¹: 2015 -2018				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2015-2016	2017	2018	Total ²
Programme Budget (US\$)	10,559,393 ³	2,624,000	3,910,500	17,093,893
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2015-2016	2017		
Number of Pneumococcal vaccines doses		698,900		
Annual Amounts (US\$)	10,559,393 ⁵	2,624,000		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable				
14. Co-financing obligations: Reference code: 1718-KHM-12c-X-C According to the co-financing policy, the Country falls within the group Preparatory transition phase self-financing.				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018
Number of vaccine doses	42,300	63,200
Number of AD syringes		
Number of re-constitution syringes		
Number of safety boxes		
Value of vaccine doses (US\$)	139,406	
Total co-financing payments (US\$) (including freight)	148,500	222,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
December 8, 2016

Cambodia Support for Immunisation supplies

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Cambodia			
2. Grant number: 17-KHM-32a-X; 18-KHM-32a-X			
3. Date of Decision Letter: December 8, 2016			
4. Date of the Partnership Framework Agreement: November 6 2013			
5. Programme title: Immunisation supplies ¹			
6. Programme duration²: 2017			
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2017	2018	Total ³
Programme Budget (US\$)	106,500	108,000	214,500
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
TOTAL immunisation supplies to be purchased with Gavi funds in each year			2017
Number of AD syringes			2,098,000
Number of safety boxes			23,100
Annual Amounts for immunisation supplies for all Gavi vaccines (US\$)			106,500

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

Immunisation supplies to be purchased with Gavi funds in each year, <u>by type of support</u>	
New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine	2017
Number of AD syringes	760,700
Number of safety boxes	8,375
Annual Amounts for immunisation supplies for Vaccine (US\$)	38,500
New Vaccine Support (NVS), DTP-HepB-Hib, 1 dose(s) per vial, LIQUID	2017
Number of AD syringes	967,700
Number of safety boxes	10,650
Annual Amounts for immunisation supplies for Vaccine (US\$)	49,000
New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID,Routine	2017
Number of AD syringes	369,600
Number of safety boxes	4,075
Annual Amounts for immunisation supplies for Vaccine (US\$)	19,000
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
10. Self-procurement: Not applicable	
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
December 8, 2016